The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma

被引:2
作者
Tascilar, M
Skinner, HG
Rosty, C
Sohn, T
Wilentz, RE
Offerhaus, GJA
Adsay, V
Abrams, RA
Cameron, JL
Kern, SE
Yeo, CJ
Hruban, RH
Goggins, M
机构
[1] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[6] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
[7] Wayne State Univ, Sch Med, Harper Hosp,Detroit Med Ctr, Karmanos Canc Inst,Dept Pathol, Detroit, MI USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: SMAD4 (also called Dpc4) is a tumor suppressor in the TGF-beta signaling(1) pathway that is genetically inactivated in similar to 55% of all pancreatic adenocarcinomas. We investigated whether prognosis after surgical resection for invasive pancreatic adenocarcinoma is influenced by SMAD4 status. Experimental Design: Using immunohistochemistry, we characterized the SMAD4 protein status of 249 pancreatic adenocarcinomas resected from patients who underwent pancreaticoduodenectomy (Whipple resection) at The Johns Hopkins Hospital, Baltimore, MD, between 1990 and 1997. The SMAD4 gene status of 56 of 249 (22%) pancreatic carcinomas was also determined. A multivariate Cox proportional hazards model assessed the relative risk of mortality associated with SMAD4 status, adjusting for known prognostic variables. Results: Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival (unadjusted median survival was 19.2 months as compared with 14.7 months in patients with pancreatic cancers lacking SMAD4 protein expression; P = 0.03). This SMAD4 survival benefit persisted after adjustment for prognostic factors including tumor size, margins, lymph node status, pathological stage, blood loss, and use of adjuvant chemoradiotherapy. The relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04). Conclusion: Patients undergoing Whipple resection for pancreatic adenocarcinoma survive longer if their cancers express SMAD4.
引用
收藏
页码:4115 / 4121
页数:7
相关论文
共 50 条
[41]   Well Differentiation and Intact Smad4 Expression Are Specific Features of Groove Pancreatic Ductal Adenocarcinomas [J].
Izumi, Sadanobu ;
Nakamura, Satoko ;
Mano, Shohei ;
Akaki, Shiro .
PANCREAS, 2015, 44 (03) :394-400
[42]   The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study [J].
Shin, Sang Hyun ;
Kim, Hwa Jung ;
Hwang, Dae Wook ;
Lee, Jae Hoon ;
Song, Ki Byung ;
Jun, Eunsung ;
Shim, In Kyong ;
Hong, Seung-Mo ;
Kim, Hyoung Jung ;
Park, Kwang-Min ;
Lee, Young-Joo ;
Kim, Song Cheol .
ONCOTARGET, 2017, 8 (11) :17945-17959
[43]   SMAD4 and its role in pancreatic cancer [J].
Xia, Xiang ;
Wu, Weidong ;
Huang, Chen ;
Cen, Gang ;
Jiang, Tao ;
Cao, Jun ;
Huang, Kejian ;
Qiu, Zhengjun .
TUMOR BIOLOGY, 2015, 36 (01) :111-119
[44]   Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis [J].
MacCurtain, Benjamin M. ;
Quirke, Ned P. ;
Thorpe, Stephen D. ;
Gallagher, Tom K. .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
[45]   Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma [J].
Weng, Shaofan ;
Wang, Hua ;
Chen, Weihong ;
Katz, Matthew H. ;
Chatterjee, Deyali ;
Lee, Jeffrey E. ;
Pisters, Peter W. ;
Gomez, Henry F. ;
Abbruzzese, James L. ;
Fleming, Jason B. ;
Wang, Huamin .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (08) :1336-1343
[46]   LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4 [J].
Zhenchong Li ;
Zuyi Ma ;
Shujie Wang ;
Qian Yan ;
Hongkai Zhuang ;
Zixuan Zhou ;
Chunsheng Liu ;
Yubin Chen ;
Mingqian Han ;
Zelong Wu ;
Shanzhou Huang ;
Qi Zhou ;
Baohua Hou ;
Chuanzhao Zhang .
Biology Direct, 19
[47]   LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4 [J].
Li, Zhenchong ;
Ma, Zuyi ;
Wang, Shujie ;
Yan, Qian ;
Zhuang, Hongkai ;
Zhou, Zixuan ;
Liu, Chunsheng ;
Chen, Yubin ;
Han, Mingqian ;
Wu, Zelong ;
Huang, Shanzhou ;
Zhou, Qi ;
Hou, Baohua ;
Zhang, Chuanzhao .
BIOLOGY DIRECT, 2024, 19 (01)
[48]   Utility of TTF-1, SMAD4, and p53 Immunohistochemistry Panel in Distinguishing Metastatic Pancreatic Ductal Adenocarcinoma to the Lung from Invasive Mucinous Adenocarcinoma [J].
Caldwell, Nicholas ;
Muto-Ishizuka, Mariko ;
Wang, Charlotte ;
Ganci, Maria ;
Rider, Anna ;
Hung, Yin ;
Shih, Angela ;
Zhan, M. Lisa ;
Mino-Kenudson, Mari .
LABORATORY INVESTIGATION, 2025, 105 (03)
[49]   Large-scale analysis for treatment strategy according to genetic alterations of KRAS and DPC4 (SMAD4) genes in pancreatic ductal adenocarcinoma. [J].
Shin, Sang Hyun ;
Kim, Song Cheol ;
Song, Ki Byung ;
Lee, Jae Hoon ;
Hwang, Dae Wook ;
Lee, Dong Joo ;
Lee, Jung Woo ;
Kim, Hyoung Eun ;
Jun, Eunsung ;
Park, Kwang-Min ;
Lee, Young-Joo .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[50]   Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis [J].
Wang, Jin-Dao ;
Jin, Ketao ;
Chen, Xiao-Ying ;
Lv, Jie-Qing ;
Ji, Ke-Wei .
ONCOTARGET, 2017, 8 (10) :16704-16711